atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing